The true death toll from COVID-19 is estimated by calculating worldwide excess mortality.

COVID-19's actual death toll: Calculating worldwide excess mortality
With a confirmed death toll of 171, COVID-19 was deemed a Public Health Emergency of International Concern (PHEIC) on January 30, 2020. By the end of 2020, this number was 1 813 188. Preliminary estimates, however, point to at least 3 million deaths worldwide in 2020 that can be directly attributed to the COVID-19 pandemic, which is 1.2 million more deaths than have been officially reported.

Based on the excess mortality projections generated for 2020, the most recent COVID-19 deaths reported to WHO now surpass 3.3 million, and as a result, we are likely dealing with a major undercount DLA Piper France

impact-covid19-healthcare-systems\sActualité
What effects will the Covid-19 pandemic have on healthcare infrastructure?
The world economy has been completely shut down by a health crisis for the first time in history, starkly illuminating how intertwined the economy and healthcare have grown. Is health now intrinsically more significant? Or is the constant stream of digital information escalating dread and affecting political decisions? Or is it because this time, the so-called "developed markets" are actually affected? These queries are crucial to placing the future of healthcare systems in context, but this article will not make an attempt to address them.

Our healthcare systems around the world were not created to handle this crisis: an unforeseen, significant health issue that demands an immediate mobilisation of resources and impacts the entire population. DebatingIncrease relative attention and spending on speciality care, and encourage innovation for smaller unmet needs and vulnerable groups in particular.
Patients with rare diseases account for less than 0.06% of the population in the US, 0.05% in the EU, and 0.04% in Japan7. In contrast, it is anticipated that over the period of 2019–24, sales of orphan drugs will have increased by 12.3% globally. Orphan pharmaceuticals are anticipated to account for one-fifth of all prescription drug sales globally by 2024, or US$242 billion8, according to projections. Parallel to this, oncology is anticipated to rise at a CAGR of 11.4% and account for over 20% of the global market by 2024.

Spend less on general prevention.
In OECD nations, less than 3% of healthcare spending was allocated to prevention in 2015. majority of theseIncrease relative attention and spending on speciality care, and encourage innovation for smaller unmet needs and vulnerable groups in particular.
Patients with rare diseases account for less than 0.06% of the population in the US, 0.05% in the EU, and 0.04% in Japan7. In contrast, it is anticipated that over the period of 2019–24, sales of orphan drugs will have increased by 12.3% globally. Orphan pharmaceuticals are anticipated to account for one-fifth of all prescription drug sales globally by 2024, or US$242 billion8, according to projections. Parallel to this, oncology is anticipated to rise at a CAGR of 11.4% and account for over 20% of the global market by 2024.

Spend less on general prevention.
In OECD nations, less than 3% of healthcare spending was allocated to prevention in 2015. majority of these